Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at UBS Group

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by research analysts at UBS Group from a “neutral” rating to a “buy” rating in a research report issued on Thursday, Benzinga reports. The firm currently has a $978.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $660.00. UBS Group’s price target would suggest a potential upside of 22.81% from the stock’s current price.

A number of other research analysts also recently weighed in on REGN. Wells Fargo & Company lifted their price target on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a report on Friday, July 31st. Cantor Fitzgerald increased their price objective on Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. JPMorgan Chase & Co. increased their price objective on Regeneron Pharmaceuticals from $900.00 to $950.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 6th. Royal Bank Of Canada raised their price objective on Regeneron Pharmaceuticals from $737.00 to $810.00 and gave the stock a “sector perform” rating in a research report on Thursday, October 8th. Finally, Robert W. Baird lifted their target price on Regeneron Pharmaceuticals from $742.00 to $761.00 and gave the company a “neutral” rating in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $845.21.

Regeneron Pharmaceuticals Trading Up 2.3%

Regeneron Pharmaceuticals stock traded up $17.98 during midday trading on Thursday, reaching $796.34. The stock had a trading volume of 798,824 shares, compared to its average volume of 822,409. The firm’s fifty day simple moving average is $791.11 and its two-hundred day simple moving average is $720.89. Regeneron Pharmaceuticals has a twelve month low of $564.00 and a twelve month high of $859.34. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The firm has a market cap of $81.99 billion, a price-to-earnings ratio of 19.68, a PEG ratio of 1.30 and a beta of 0.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.16 by $4.13. The company had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company’s revenue was up 16.7% on a year-over-year basis. During the same period in the previous year, the business earned $12.81 EPS. Equities analysts anticipate that Regeneron Pharmaceuticals will post 47.93 EPS for the current fiscal year.

Insider Activity at Regeneron Pharmaceuticals

In other news, EVP Marion Mccourt sold 1,215 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $1,032,750.00. Following the completion of the sale, the executive vice president directly owned 13,134 shares of the company’s stock, valued at $11,163,900. This trade represents a 8.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Andrew J. Murphy sold 4,147 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $772.70, for a total value of $3,204,386.90. Following the sale, the insider owned 47,833 shares of the company’s stock, valued at approximately $36,960,559.10. This represents a 7.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 8,093 shares of company stock valued at $6,506,845. 6.97% of the stock is owned by insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SHP Wealth Management bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $26,000. Western Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at $26,000. Armstrong Advisory Group Inc. grew its position in Regeneron Pharmaceuticals by 466.7% in the third quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 28 shares during the period. Trust Co. of Vermont bought a new stake in Regeneron Pharmaceuticals in the second quarter valued at $29,000. Finally, Mowery & Schoenfeld Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals in the second quarter valued at $29,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: UBS initiated a “Buy” rating on Regeneron, arguing that Wall Street is undervaluing the long-term growth potential of Dupixent, the company’s key immunology drug marketed with Sanofi. Regeneron a new buy at UBS as Street undervalues Dupixent’s future
• Positive Sentiment: Regeneron has reportedly finished paying down its balance owed to Sanofi. That should allow the company to retain more of the economics from the partnership and could improve reported revenue and profitability going forward. What Could Send Regeneron Stock Higher?
• Positive Sentiment: Analysts are anticipating double-digit bottom-line growth when Regeneron reports third-quarter results later this month, creating a near-term catalyst if earnings and guidance exceed expectations. What to Expect From Regeneron Pharmaceuticals’ Next Quarterly Earnings Report
• Neutral Sentiment: A review of second-quarter biotechnology results included Regeneron among industry performers, but the available report summary does not identify a new company-specific catalyst. Q2 Earnings Highlights: Regeneron Vs The Rest Of The Biotechnology Stocks
• Negative Sentiment: Executive Andrew Murphy sold 4,147 Regeneron shares worth approximately $3.2 million, reducing his direct holdings by 7.98%. The transaction occurred under a pre-arranged Rule 10b5-1 plan, which lessens its significance as a bearish signal. SEC insider transaction filing

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.